Form 4: Forbion Funds Reduce Stake in NewAmsterdam Pharma Co N.V. (NAMS) Through Open Market Sales
SEC Form 4
Forbion Growth Opportunities Fund I Cooperatief U.A. and Forbion Capital Fund IV Cooperatief U.A., through related entities, have sold a portion of their NewAmsterdam Pharma Co N.V. shares on the open market between December 20 and December 24, 2024, pursuant to a pre-arranged Rule 10b5-1 trading plan.
Summary
- Forbion Growth Opportunities Fund I Cooperatief U.A. and Forbion Capital Fund IV Cooperatief U.A., through ForGrowth NAP B.V. and PoolCo, executed a series of sales of NewAmsterdam Pharma Co N.V. (NAMS) ordinary shares.
- The sales occurred between December 20 and December 24, 2024.
- These transactions were conducted under a pre-existing Rule 10b5-1 trading plan adopted on March 28, 2024.
- The weighted average sale prices ranged from $25.4904 to $26.1274 per share.
- The total number of shares sold was approximately 90,000.
- Following these transactions, ForGrowth NAP B.V. continues to beneficially own a significant number of NewAmsterdam Pharma Co N.V. shares, totaling 10,760,928.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing share sales by major shareholders. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about transactions.
Industry Context
This filing indicates activity by major shareholders, which is common in the pharmaceutical industry as investment funds manage their portfolios. Monitoring such transactions can provide insights into investor sentiment regarding the company's prospects.
Comparison to Industry Standards
- Rule 10b5-1 trading plans are a common tool used by insiders to sell shares while avoiding accusations of trading on non-public information; many pharmaceutical companies have executives and major shareholders utilizing these plans.
- The size and frequency of the sales are not unusual for institutional investors managing large positions in publicly traded companies.
- Comparable companies in the pharmaceutical sector often see similar filings related to insider transactions.
Stakeholder Impact
- The share sales could potentially exert downward pressure on the stock price in the short term.
- The continued significant ownership by Forbion suggests ongoing confidence in the company's long-term prospects.
Key Dates
| Date | Description |
|---|---|
| 2024-03-28 | Date of adoption of Rule 10b5-1 trading plan by NAP PoolCo B.V. |
| 2024-12-20 | Date of first transaction reported |
| 2024-12-23 | Date of transaction reported |
| 2024-12-24 | Date of transaction reported |
| 2024-12-26 | Date of signatures on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.